Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics

Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal.Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its acquisition…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Laura Testa

Author: Laura Testa

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here